Fountainhead AM LLC Raises Stock Holdings in Bausch Health Companies Inc. (NYSE:BHC)

Fountainhead AM LLC lifted its holdings in Bausch Health Companies Inc. (NYSE:BHC) by 4.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 359,516 shares of the company’s stock after buying an additional 15,976 shares during the quarter. Bausch Health Companies makes up about 0.8% of Fountainhead AM LLC’s portfolio, making the stock its 23rd biggest position. Fountainhead AM LLC owned 0.10% of Bausch Health Companies worth $2,883,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Goldentree Asset Management LP increased its holdings in Bausch Health Companies by 19.6% during the 3rd quarter. Goldentree Asset Management LP now owns 23,987,462 shares of the company’s stock worth $197,177,000 after purchasing an additional 3,931,234 shares during the period. Nomura Holdings Inc. increased its holdings in Bausch Health Companies by 67.7% during the 3rd quarter. Nomura Holdings Inc. now owns 18,086,000 shares of the company’s stock worth $148,667,000 after purchasing an additional 7,303,015 shares during the period. Hudson Bay Capital Management LP increased its holdings in Bausch Health Companies by 35.3% during the 3rd quarter. Hudson Bay Capital Management LP now owns 11,500,000 shares of the company’s stock worth $94,530,000 after purchasing an additional 3,000,000 shares during the period. Vanguard Group Inc. increased its holdings in Bausch Health Companies by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 11,487,768 shares of the company’s stock worth $94,429,000 after purchasing an additional 175,489 shares during the period. Finally, Mizuho Markets Americas LLC purchased a new position in Bausch Health Companies during the 3rd quarter worth $57,540,000. 78.65% of the stock is currently owned by hedge funds and other institutional investors.

Bausch Health Companies Stock Up 0.9 %

Shares of Bausch Health Companies stock traded up $0.08 during trading on Tuesday, reaching $8.53. The company’s stock had a trading volume of 4,025,446 shares, compared to its average volume of 2,802,447. The company has a market cap of $3.12 billion, a price-to-earnings ratio of -5.27 and a beta of 0.85. Bausch Health Companies Inc. has a 1-year low of $5.57 and a 1-year high of $11.46. The company has a 50-day simple moving average of $9.29 and a two-hundred day simple moving average of $8.16.

Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings data on Thursday, February 22nd. The company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.14. The firm had revenue of $2.41 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Bausch Health Companies had a positive return on equity of 5,147.48% and a negative net margin of 6.76%. The business’s quarterly revenue was up 9.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.02 EPS. As a group, analysts anticipate that Bausch Health Companies Inc. will post 3.95 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on BHC shares. Jefferies Financial Group cut their price target on Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, February 20th. StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Wednesday, February 7th. Finally, Royal Bank of Canada cut their price target on Bausch Health Companies from $12.00 to $11.00 and set a “sector perform” rating on the stock in a report on Tuesday.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.